Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602747 | 0.83 | IDH2 (0.33) | ACLY | |
| SCHEMBL3602959 | 0.81 | IDH2 (0.38) | L3MBTL1KMT2AALDH1A1HPGDHTT | |
| SCHEMBL3596237 | 0.80 | PTGDR2 (0.39) | CTSAGPBAR1 | |
| SCHEMBL3594636 | 0.79 | PTGDR2 (0.38) | — | |
| SCHEMBL3593302 | 0.78 | PTGDR2 (0.37) | GPBAR1 | |
| SCHEMBL4139396 | 0.78 | RXRA (0.35) | L3MBTL1GPBAR1 | |
| SCHEMBL3596958 | 0.77 | L3MBTL1 (0.36) | L3MBTL1GPBAR1 | |
| SCHEMBL3593299 | 0.77 | RXRA (0.34) | ALDH1A1GAACTSAKDM4EGPBAR1 | |
| SCHEMBL3597052 | 0.76 | IDH2 (0.36) | SMN1; SMN2KMT2AALDH1A1HPGDTP53 | |
| SCHEMBL3597872 | 0.76 | RXRA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | claimed |
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | SLCO1B3, SLCO1B1, SLC10A6 | NPC1 1356/4885SMN1; SMN2 3658/4885L3MBTL1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.